Weninger Stacie, Sperling Bjorn, Alexander Robert, Ivarsson Magnus, Menzies Fiona M, Powchik Peter, Weber Christopher J, Altar C Anthony, Crystal Ronald G, Haggarty Stephen J, Loring Jeanne, Bain Lisa J, Carrillo Maria C
FBRI Cambridge Massachusetts USA.
H. Lundbeck A/S Copenhagen Denmark.
Alzheimers Dement (N Y). 2020 Oct 12;6(1):e12090. doi: 10.1002/trc2.12090. eCollection 2020.
As knowledge of Alzheimer's disease (AD) progression improves, the field has recognized the need to diversify the pipeline, broaden strategies and approaches to therapies, as well as delivery mechanisms. A better understanding of the earliest biological processes of AD/dementia would help inform drug target selection. Currently there are a number of programs exploring these alternate avenues. This meeting will allow experts in the field (academia, industry, government) to provide perspectives and experiences that can help elucidate what the pipeline looks like today and what avenues hold promise in developing new therapies across the stages of AD. The focus here is on Active Immunotherapies and Alternative Therapeutic Modalities. This topic includes active vaccines, antisense oligomers, and cell-based therapy among others, and highlights new clinical developments that utilize these modalities.
随着对阿尔茨海默病（AD）进展的认识不断提高，该领域已经意识到需要使研发渠道多样化，拓宽治疗策略和方法以及给药机制。更好地了解AD/痴呆症最早的生物学过程将有助于指导药物靶点的选择。目前有许多项目在探索这些替代途径。本次会议将使该领域的专家（学术界、产业界、政府）能够提供观点和经验，有助于阐明如今的研发渠道状况以及在AD各个阶段开发新疗法方面哪些途径具有前景。这里的重点是主动免疫疗法和替代治疗方式。本主题包括活性疫苗、反义寡聚核苷酸和细胞疗法等，并突出了利用这些方式的新临床进展。
